Corestemchemon, Inc.
8 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Evaluate the Safety and Tolerability of CE211NS21 in Patients With AQP4-IgG-positive NMOSD Relapse (NCT07595965) | Corestemchemon, Inc. | 2026-12-01 |
| Evaluate the Safety of Neuronata-R® Inj. Suspended With HypoTHermosol® FRS (HTS-FRS) in Patients With ALS (NCT06676423) | Corestemchemon, Inc. | 2022-11-09 |
| Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS (NCT04745299) | Corestemchemon, Inc. | 2021-02-24 |
| Long-term Follow-up of Phase 1 Clinical Trial of CS10BR05(CS10BR05-MSA101) (NCT04495582) | Corestemchemon, Inc. | 2018-08-28 |
| Safety and Tolerability of CS10BR05 Inj. in Subjects with Multiple System Atrophy (NCT03265444) | Corestemchemon, Inc. | 2018-04-13 |
| Long-term Follow-up for Evaluating the Safety of CS20AT04 in Subject with Lupus Nephritis (NCT04522505) | Corestemchemon, Inc. | 2017-11-29 |
Track Corestemchemon, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.